Efficacy Study of Panax Ginseng to Boost Antipsychotics Effects in Schizophrenia
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00401089 |
Recruitment Status :
Completed
First Posted : November 17, 2006
Last Update Posted : December 12, 2012
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Schizophrenia Schizoaffective Disorder Tardive Dyskinesia Insulin Resistance Obesity | Drug: Panax Ginseng | Phase 1 Phase 2 |
Schizophrenia is a serious mental disorder affecting individuals in multiple ways: behavior control, emotional and information processing and the functional levels conforming to societal norms. Despite recent advances in medication therapy in treating the target symptoms of schizophrenia , subsets of patients diagnosed with schizophrenia continue to exhibit negative symptoms ( social withdrawal,apathy, lack of drive )and cognitive impairment (memory, attention, judgment and reasoning). Recently, there has been interest to explore the efficacy of avenue of dietary and herbal supplements with known pharmacological actions in treatment and prevention of neuropsychiatric disorders, especially bipolar and schizophrenia.
We hypothesize that Panax Ginseng , with multiple interactions with chemical pathways in the brain described as neurotransmitter systems (Dopamine, GABA and NMDA ) can improve the residual symptoms of schizophrenia when added to the antipsychotics currently used in the treatment of schizophrenia. Furthermore, in view of previous studies of Ginseng in enhancing memory , we hypothesize that the standardized formulation of Ginseng (Ginsana-115 from Boehringer Ingelheim-Pharmaton,Switzerland ) will optimize the antipsychotics in cognition impairment and negative symptoms. In the 18-week RCT cross-over study, schizophrenic subjects will be treated with either Ginsana-115 ( 100 mg or 200 mg by oral route) or placebo in a cross-over design. we plan to recruit 60 subjects diagnosed as schizophrenia from the four sites : London-St. Thomas, Ontario, Canada; Kingston Ontario Canada; Thunderbay, Ontario Canada and Middlesex, United Kingdom.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 60 participants |
Allocation: | Randomized |
Intervention Model: | Crossover Assignment |
Masking: | Double (Participant, Investigator) |
Primary Purpose: | Treatment |
Official Title: | A Placebo-controlled Cross Study of Panax Ginseng in Augmentation of Antipsychotics in 60 Partially Treatment Responsive Patients With Schizophrenia |
Study Start Date : | December 2002 |
Actual Primary Completion Date : | December 2006 |
Actual Study Completion Date : | October 2007 |

Arm | Intervention/treatment |
---|---|
Experimental: Ginsana-115
Ginsana-115 (Panax Ginseng formulation obtained from Boehringer Ingelheim Pharmaton Inc. Switzerland )is available in oral dosage form of capsules. Two dosages of Ginsana-115 will be tested: 100 mg once daily oral dosage ( 1 100-mg Ginsana-115 capsule) and 200 mg once daily dosage ( 2 100-mg Ginsana-115 capsule). The total duration of each dosage is 8 weeks.
|
Drug: Panax Ginseng
The standardized extract of Panax Ginseng was formulated by Boehringer Ingelheim Pharmaton, Switzerland and fulfills the criteria of cGMP. Quality control and safety are monitored regularly by Boehringer Ingelheim Pharmaton.
Other Name: Ginsana-115 |
Placebo Comparator: Sugar Pill
Placebo capsules formulated identical to the active drug: Ginsana-115 are to be obtained from Boehringer Ingelheim Pharmaton, Switzerland. Two dosages of Placebo capsules will be administered once daily for 8 weeks : a) Placebo 100 mg capsule: 1 placebo capsule daily; b) Placebo 200 mg capsule: 2 placebo-capsule daily
|
Drug: Panax Ginseng
The standardized extract of Panax Ginseng was formulated by Boehringer Ingelheim Pharmaton, Switzerland and fulfills the criteria of cGMP. Quality control and safety are monitored regularly by Boehringer Ingelheim Pharmaton.
Other Name: Ginsana-115 |
- Neuro-Cognitive Screening Test [ Time Frame: wk 0, 8, crossover , wk 2, 8 ]The battery of neurocognitive tests is to be administered in a computerized format to the subjects at various time intervals
- PANSS Positive Negative Syndrome Scale [ Time Frame: -wk 2, wk 0, 2, 5,8 crossover wk 2,5,8 ]Changes in PANSS is the co-primary outcome measure
- SANS [ Time Frame: Change from baseline to week 8, cross-over; week 11-week 18. ]We list SANS as the co-primary outcome measure. We cross-validate the changes in SANS with PANSS
- HAM-D Hamilton Depression Rating Scale [ Time Frame: -wk2, wk0, 2, 5, 8 crossover wk 2, 5, 8 ]We will correlate the changes in HAM-D with PANSS changes
- BPRS Brief Psychiatric Rating Scale [ Time Frame: -wk 2, wk 0, 2,5,8 crossover wk 2, 5, 8 ]This is a measure of the global change if any of the psychiatric symptoms during the 18-week period
- QLS Quality of Life Scale [ Time Frame: wk 0, 8 crossover wk 8 ]
- AIMS Abnormal Involuntary Movement Scale [ Time Frame: -wk 2, wk 0, 2, 5, 8 crossover wk 2, 5, 8 ]We examined whether subjects experienced any changes in dyskinetic movements
- SAS Simpson Angus Scale for Extrapyramidal Symptoms [ Time Frame: -wk 2, wk 0, 2,5,8 crossover wk 2,5,8 ]
- Blood Chemistry Profile: CBC, kidney function,lipid profile, fasting glucose insulin [ Time Frame: -wk 2, wk 8 crossover wk 8 ]We examined whether the subjects participated in the study experienced any changes in indices of metabolic-metabolic functions
- BMI Body Mass index [ Time Frame: Change from baseline to end of 18-week period ]BMI will be measured along with anthropometric measures: % total body water;% total fat, % muscle mass

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 65 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Male or female
- age 18-65 years
- DSM-IV diagnosis of Schizophrenia
- SANS score greater than 30
Exclusion Criteria:
- Current (past 12 months) substance use disorder
- Except nicotine dependence
- Major medical disorders : hematological disorder
- Chronic active hepatitis, acute hepatitis, cirrhosis of liver, AIDS
- Pregnancy and breast-feeding
- Neurological disorders including epilepsy
- traumatic brain injury
- HAM-D score greater than 24

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00401089
Canada, Ontario | |
Queen's University | |
Kingston, Ontario, Canada | |
Regional Mental Health Care London | |
St. Thomas, Ontario, Canada, N5P 3V9 | |
Northern Ontario Medical School | |
Thunder Bay, Ontario, Canada | |
United Kingdom | |
Northwick Park Hospital | |
Harrow, Middlesex, United Kingdom, HA13UJ |
Principal Investigator: | Simon S Chiu, MD PhD | Lawson Health Research Institute London Ontario Canada |
Responsible Party: | Simon Chiu, University of Western Ontario London Ontario; Research Scientist, Lawson Health Research Institute London Ontario Canada, Lawson Health Research Institute |
ClinicalTrials.gov Identifier: | NCT00401089 |
Other Study ID Numbers: |
R-02-285 |
First Posted: | November 17, 2006 Key Record Dates |
Last Update Posted: | December 12, 2012 |
Last Verified: | December 2012 |
negative symptoms schizophrenia Atypical antipsychotics Neurocognition impairment obesity risk factor Diabetes insulin resistance schizophrenia |
Dyskinesias Tardive Dyskinesia Insulin Resistance Schizophrenia Psychotic Disorders Schizophrenia Spectrum and Other Psychotic Disorders Mental Disorders Hyperinsulinism |
Glucose Metabolism Disorders Metabolic Diseases Movement Disorders Central Nervous System Diseases Nervous System Diseases Neurologic Manifestations Dyskinesia, Drug-Induced |